(MedPage Today) — The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy.
A B-cell maturation antigen (BCMA)-directed bispecific antibody…
